Abstract

In current immunotherapy, a promising direction is therapy using chimeric antigen receptor T cells (CAR-T). Among malignant hematological diseases, even at advanced stages and resistant/recurrent forms, the use of CAR-T demonstrates high efficiency. The observed clinical success in patients with hematologic malignancies not only determines the ever-increasing list of indications for the use of CAR-T in this group of patients, but also motivates the study of this treatment method in solid oncology and autoimmune diseases. This review examines the history of the emergence and development of CAR-T, the path from the idea of creation to registration to clinical use.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.